- Home
- UHG vs CGEN Comparison
UHG vs CGEN Comparison
Compare UHG & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UHG | CGEN |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.1M | 148.7M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | UHG | CGEN |
|---|---|---|
| Price | $2.10 | $1.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 311.2K | ★ 549.7K |
| Earning Date | 03-11-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $418,113,017.00 | $6,903,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $164.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.99 | $1.13 |
| 52 Week High | $4.78 | $2.66 |
Technical Indicators
Market Signals| Indicator | UHG | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 64.08 | 41.66 |
| Support Level | $1.91 | $1.58 |
| Resistance Level | $2.16 | $2.08 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 78.10 | 15.20 |
Price Performance
Historical ComparisonAbout UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.